CellProtect is a novel drug candidate for treatment of multiple myeloma. It is based on autologous NK cells that are expanded and their cytotoxic activity restored through a patented process. The cells are then infused into the patient to treat the disease. CellProtect is currently investigated in a Phase I clinical trial in multiple myeloma patients at the Karolinska University Hospital in Huddinge, Sweden.
CellProtect has experimental support from animal models and ex vivo studies where CellProtect has been shown to kill multiple myeloma cells. CellProtect will be used as an adjunct treatment to an autologous stem cell transplant, which is the standard of care for patients that are eligible for a transplant. The goal is to prolong time to remission without affecting quality of life for the patient, although CellProtect also has the potential to cure multiple myeloma. It is expected to be complementary to current treatments such as lenalidomide and bortezomib.
CellProtect is manufactured under GMP conditions at the core facility Vecura at Karolinska University Hospital. The drug product has nine months documented stability at frozen conditions. The company has filed for Orphan Drug designation in the EU and is currently awaiting a response.